Bicycle Therapeutics Future Growth
Future criteria checks 2/6
Bicycle Therapeutics is forecast to grow earnings and revenue by 19.1% and 51.1% per annum respectively. EPS is expected to grow by 22.6% per annum. Return on equity is forecast to be -48.1% in 3 years.
Key information
19.1%
Earnings growth rate
22.6%
EPS growth rate
| Biotechs earnings growth | 27.3% |
| Revenue growth rate | 51.1% |
| Future return on equity | -48.1% |
| Analyst coverage | Good |
| Last updated | 21 Jan 2025 |
Recent future growth updates
Recent updates
We're Not Very Worried About Bicycle Therapeutics' (NASDAQ:BCYC) Cash Burn Rate
Jan 06
Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern
Nov 07Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 03Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 23Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 139 | -268 | -188 | -130 | 10 |
| 12/31/2026 | 50 | -282 | -232 | -192 | 12 |
| 12/31/2025 | 32 | -244 | -211 | -168 | 13 |
| 12/31/2024 | 37 | -178 | -179 | -129 | 13 |
| 9/30/2024 | 37 | -166 | -204 | -203 | N/A |
| 6/30/2024 | 40 | -165 | -165 | -164 | N/A |
| 3/31/2024 | 42 | -168 | -86 | -85 | N/A |
| 12/31/2023 | 27 | -181 | -64 | -61 | N/A |
| 9/30/2023 | 25 | -162 | -48 | -44 | N/A |
| 6/30/2023 | 23 | -140 | -55 | -48 | N/A |
| 3/31/2023 | 15 | -124 | -122 | -106 | N/A |
| 12/31/2022 | 14 | -113 | -105 | -86 | N/A |
| 9/30/2022 | 15 | -101 | -85 | -66 | N/A |
| 6/30/2022 | 16 | -87 | -54 | -39 | N/A |
| 3/31/2022 | 14 | -78 | -34 | -27 | N/A |
| 12/31/2021 | 12 | -67 | -17 | -15 | N/A |
| 9/30/2021 | 12 | -66 | -22 | -21 | N/A |
| 6/30/2021 | 11 | -62 | -54 | -53 | N/A |
| 3/31/2021 | 11 | -56 | -54 | -53 | N/A |
| 12/31/2020 | 10 | -51 | -19 | -18 | N/A |
| 9/30/2020 | 12 | -38 | -7 | -6 | N/A |
| 6/30/2020 | 9 | -37 | -8 | -7 | N/A |
| 3/31/2020 | 9 | -35 | -4 | -2 | N/A |
| 12/31/2019 | 14 | -31 | -30 | -29 | N/A |
| 9/30/2019 | 10 | -33 | -34 | -33 | N/A |
| 6/30/2019 | 11 | -31 | -28 | -26 | N/A |
| 3/31/2019 | 11 | -26 | -25 | -24 | N/A |
| 12/31/2018 | 7 | -22 | -27 | -26 | N/A |
| 9/30/2018 | 7 | -21 | -20 | -19 | N/A |
| 12/31/2017 | 2 | -16 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCYC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCYC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCYC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCYC's revenue (51.1% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: BCYC's revenue (51.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BCYC is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 01:10 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bicycle Therapeutics plc is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Kalpit Patel | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |